Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Investor Presentation (2025)
47 slides from Piramal Pharma's investor presentation, 2025
Slide 1: Investor Presentation FY2025
Investor Presentation FY2025
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Piramal Pharma - Phases of our Evolution
Piramal Pharma - Phases of our Evolution Overview 1988 2010 2020 2022 Piramal Healthcare Piramal Enterprises Ltd. Piramal Pharma Ltd. CDMO Domestic Formulations CDMO Piramal Pharma Financial Services Pharma Solutions (CDMO) Complex Hospital Generics (CHG) Nicholas CDMO Wholesale Lending Laboratories
Slide 4: Three-Pronged Business Model
Three-Pronged Business Model Overview Contract Development and Manufacturing Organization Complex Hospital Generics Piramal Consumer Healthcare Innovation Focused Integrated CDMO with Global Operations A Critical Care Company Consumer Health and Wellness Company3 CDMO Inhalation Anesthesia Intrathec
Slide 5: Diversified Revenue with a Large Customer Base
Diversified Revenue with a Large Customer Base Overview 17 100+ ~500 6,000+ ~180K Countries with Manufacturing and commercial presence PCH Customers Countries with CDMO Customers CHG Customers Development (Chemists and Commercial (Hospitals) Sites1 CDMO Presence cosmetics shops) Revenue by Geography
Slide 6: Global Network of Facilities – Good Blend of East and West
Global Network of Facilities – Good Blend of East and West 17 Manufacturing & Development Facilities Across North America, UK / Europe, and India Overview 5 2 10 CDMO Grangemouth Morpeth Ahmedabad1 Pithampur Dahej Rabale Aurora Turbhe Digwal Bethlehem Mahad Hyderabad1 Lexington Sellersville Ennore C
Slide 7: Best-in-Class Quality Track Record
Best-in-Class Quality Track Record Overview 46 377 USFDA Zero 165 total regulatory inspections customer audits in OAIs1,2 CDMO inspections1 successfully FY25 cleared1 CHG Successfully cleared 46 USFDA inspections, 377 total regulatory inspections, and 1,900+ customer audits since the ✓ beginning of
Slide 8: Track Record of Organic and Inorganic Expansion
Track Record of Organic and Inorganic Expansion Successfully Integrated Over 15 M&A Transactions in the Last 10 Years Overview Acquisition Business Portfolio of OTC brands from Pfizer Rationale PCH 100% stake in Convergence Hemmo CDMO Little's and Expand OTC Chemicals (Dahej Naturolax portfolio Pharm
Slide 9: Value Creation from Acquired Assets Across Businesses
Track Record of Organic and Inorganic Expansion Value Creation from Acquired Assets Across Businesses Overview CDMO Business CDMO CHG PCH CHG Ash Stevens (Riverview facility, 100% stake in Convergence Chemicals Little’s - Baby care brand Acquisition Michigan, US) (Dahej facility) PCH US$ 2x+ ₹ 195 U
Slide 10: Accelerating Climate Action
Accelerating Climate Action Renewable Low Carbon Energy Efficiency Overview Energy Projects Fuel Switch & Offsets 30%-42% • Ennore & Dahej: Solar- SBTi Approved Targeted reduction in Scope 1, 2 & 3 GHG wind hybrid • Pithampur: Rooftop solar • Digwal: Switched from coal-fired boiler to operate on bio
Slide 11: Inclusion & Belonging, Human Rights, Occupational Health & Safety
Inclusion & Belonging, Human Rights, Occupational Health & Safety PCC Digwal Overview CDMO CHG 30% Zero 0.05 PCH Women representation in Human rights violations- Child Lost Time Injury Rate (LTR), Board and 20% women labour, forced labour, 45% reduction over FY24 representation in overall discrimina
Slide 12: Focus on Patient and Customer Centricity: Source of Differentiation
Focus on Patient and Customer Centricity: Source of Differentiation Overview Focusing on Patient-centricity and Customer-centricity drives our organization to provide flexible high-quality service ✓ while aligning us with our customer partners on our shared goal of serving patients ⚫ Expanding acces
Slide 13: Financial Aspirations for FY2030
Financial Aspirations for FY2030 US$ 2+ Bn Global Pharma, Health & Wellness Company by FY2030 Overview Vision We aspire to be amongst top 10 companies in our addressable markets 3x Over 3x Growth in 2x More than Double the 1x Reduce Leverage on CDMO EBITDA Revenues the Balance Sheet ~25% US$ 2+ Bn ~
Slide 14: Strategic Goals for FY2030
US$ 2+ Bn Company with 25% EDITDA Margin by FY2030 Strategic Goals for FY2030 Overview US$ 1.2 Bn revenues with ~25% US$ 600 Mn revenues with 25%+ US$ 200 Mn1 revenues with EBITDA margin EBITDA margin double-digit EBITDA margin CDMO CDMO CHG PCH CHG PCH Emerge as a fast-growing, innovation- Become a
Slide 15: Key Investment Highlights
Key Investment Highlights Overview 1 Strong promoter group with over 35 years of demonstrated ability to build scalable and differentiated businesses 2 CDMO Presence in large multi - billion dollar size attractive industry segments with promising tailwinds 3 Globally diversified network of facilities
Slide 16: CDMO
6 Piramal Pharma Limited
Slide 17: Global CDMO Market
Global CDMO Market Overview Global CDMO Market - US$ 250 Billion by 2030 Global CDMO Market1 Global CDMO Market Expected to Grow at 7-8% CAGR CDMO (In US$ Bn) Growth in global pharmaceutical market - increasing chronic and age-related disorders Rising investments in R&D to develop advance therapeuti
Slide 18: Broad Archetypes of CDMO Companies
Broad Archetypes of CDMO Companies Overview Integrated Services CDMO Technology Specialists End-to-end offerings across lifecycle of molecule Value Maximisers (Discovery, Development, Pharma Players Commercial manufacturing) Offering CDMO Strong capability in Focused on: CHG Services specialized techn
Slide 19: Service Offerings Across the Lifecycle of the Molecule
Service Offerings Across the Lifecycle of the Molecule Overview Discovery Development Commercial Manufacturing On-Patent Off-Patent Pre-Clinical Phase 1 Phase 2 Phase 3 Launch Commercial Commercial CDMO Comprehensive Clinical development services for API and Ability to manufacture across a wide range
Slide 20: Deep Pipeline of Development Projects across Multiple Phases
Deep Pipeline of Development Projects across Multiple Phases Revenue by Services Building Development Pipeline Across Clinical Phases Overview Others1, 17% Pre-clinical, 1% Pre-Clinical Phase I Phase II Phase III 2% 54% Innovation 25% FY25 2.8x 145 related CDMO Development work Revenue by 27% Phase
Slide 21: Global Network of Sites to Offer Integrated Services
Global Network of Sites to Offer Integrated Services Overview UK / Europe 2 Facilities 5. Grangemouth 6. Morpeth Total 15 Facilities 5 CDMO 1 2 6 3 4 India 9 Facilities CHG 7 14 8 7. Ahmedabad1 8. Rabale North 4 Facilities 9 11 America 12 9. Turbhe 10. Mahad 10 13 1. Aurora 2. Sellersville 11. Digwa
Slide 22: Building Capabilities Across Differentiated Offerings
Building Capabilities Across Differentiated Offerings Overview Revenue (US$ mn) from Contribution of Differentiated Offerings Differentiated Offerings to CDMO revenue Potent sterile Peptide injectables CDMO High Potent Differentiated On-patent API CHG API development and (HPAPI) Offerings manufactur
Slide 23: Amongst Leading Integrated ADC Companies
Amongst Leading Integrated ADC Companies - 20+ Yrs. of Experience We Offer Fully Integrated ADC Solutions - Payload-linker, mAb, ADC Drug Substance, and Fill-finish Overview 1,000+ 350+ 200+ 30+ 60+ Total batches, of Distinct conjugates Different ADC Different toxin/ CDMO which 350+ are Clinical GMP b
Slide 24: Diversified Blue Chip Customer Base
Diversified Blue Chip Customer Base Customer Mix Customer Mix Revenue Concentration Overview #1 22% Generics 59% of revenue from Big Over 500 30% #2 customers Pharma and Emerging 5% Biopharma across segments #3 Others 4% CDMO Big Pharma 52% #4 43% 3% Others 11% Top 5-10 14% Emerging Biopharma 16% CH
Slide 25: Customer Led Investments in Capabilities and Capacities
Customer Led Investments in Capabilities and Capacities Overview Digwal Lexington Riverview CDMO Expand API Enhance Sterile Expand HP API Capacities Fill-Finish Capacities Capacities CHG Aurangabad Turbhe Multisite New API Offer CDMO Integrated Site in India Services ADC PCH services Joint Venture 2
Slide 26: Aspirations for FY2030
Aspirations for FY2030 Overview Become a US$ 1.2 Billion CDMO Company with ~25% EBITDA Margin by FY2030 Driven By CDMO CHG PCH Innovation Integrated Differentiated Customer Margin Cross Related Work Services Offerings Delight Enhancement Selling Joint Venture While maintaining our Best-in-Class Qualit
Slide 27: Complex Hospital Generics
Complex Hospital Generics
Slide 28: Differentiated Portfolio – Limited Competition, Superior Margins
Differentiated Portfolio – Limited Competition, Superior Margins Revenue by Product Segment Revenue by Geography Overview % FY25 CHG Revenue Inhalation Anesthesia Intrathecal Therapy Others 20% (67%) (15%) CDMO India 5% FY25 CHG US 56% Revenue Japan CHG 4% Injectable Anesthesia and Other Speciality
Slide 29: Commercial Presence in Over 100 Countries
Commercial Presence in Over 100 Countries Overview Worldwide Marketing and Distribution Network Established channel relationships and robust commercial infrastructure CDMO Direct sales force in the US with strong GPO relationships CHG Direct to market access in key European countries PCH Countries w
Slide 30: Amongst Leading Inhalation Anesthesia Companies in the World
Amongst Leading Inhalation Anesthesia Companies in the World ~US$ 1 Bn Global IA Market ~US$ 850+ Mn Global Sevoflurane Market Overview Leading Player in Sevoflurane in the US Desflurane 12% China US 31% Isoflurane 21% CDMO 2% CHG Sevoflurane RoW 86% 48% Others 26% 44% PCH US$ 400 Mn Market Opportun
Slide 31: Our Strengths in Inhalation Anesthesia: Vertical Integration
Our Strengths in Inhalation Anesthesia Vertical Integration – Better Control on Cost and Supply Chain Overview CDMO CHG KSM Manufacturing Sevoflurane and Desflurane Sevoflurane and Isoflurane Dahej, India Bethlehem, US Digwal, India PCH Expanded In-house Capacities to Capture Demand in Emerging Markets
Slide 32: Our Strengths in Inhalation Anesthesia: Distribution Network
Our Strengths in Inhalation Anesthesia Extensive Distribution Network and Strong Relationships with Hospitals & GPOs Overview CDMO Commercial Presence in Relationship with 6,000+ Detailed Understanding of 100+ Countries Hospital & GPOs Globally Market Operations CHG Drug Device Combination - Dedicat
Slide 33: Intrathecal Therapy
Intrathecal Therapy Overview Leading Player in the Intrathecal Baclofen Market in the US Intrathecal therapy provides treatment options to patients suffering from Spasticity (involuntary muscle contractions that cause stiffness) and Dystonia (muscle contractions that can result in twisted or abnormal
Slide 34: Injectable Anesthesia & Pain Management Portfolio
Injectable Anesthesia & Pain Management Portfolio Overview Branded Portfolio with Leadership Position in Select Markets Brands Products Sold in 50+ Countries Dipidolor® (Piritramide) Sublimaze® CDMO Market Size1 of US$ 140 Mn (Fentanyl Citrate) Rapifen® (Alfentanil Hydrochloride) Sufenta® Key market
Slide 35: Building Portfolio of Differentiated and Specialty Portfolio
Building Portfolio of Differentiated and Specialty Portfolio Select Examples of Our Experience in Overview Differentiated & Specialty Products Focus on Differentiated & Specialty Products • E.g. 505(b)(2)’s, Complex generics, differentiated generics, Gablofen Mitigo branded products to fit our sales
Slide 36: Aspirations for FY2030
Aspirations for FY2030 Overview Become a US$ 600 Million Critical Care Company with 25%+ EBITDA Margin by FY2030 Driven By CDMO CHG PCH Leadership in Defend & Expand Market Investment in Productivity and Inhalation Share in Intrathecal & Differentiated and Cost Optimization Anesthesia Injectable Pai
Slide 37: Piramal Consumer Healthcare
v Piramal Consumer Healthcare
Slide 38: Fast Growing Consumer Healthcare Company
Fast Growing Consumer Healthcare Company Overview Self-Funded Business with Annual Revenues of about ₹1,100 Crore 21%+ CAGR Building Scale: 1,093 CDMO From 3 brands and about ₹ 100 Cr sales in 2008 to 25+ brands and about ₹ 1,100 Cr sales Revenue Growth 345 Sales have almost tripled in the last 5 ye
Slide 39: Diversified Portfolio in Large and Attractive Healthcare Segments
Diversified Portfolio in Large and Attractive Healthcare Segments Kids Wellness Skincare Women’s Health Overview i-pill i-activ Lacto Calamine Contraceptive Menstrual cups and Lotions, Facewash, Sunscreen Pill sanitary pads Littles Wipes, Masks, Bodywash, Eye Wipes, Toys, Diapers, Care Feeding bottl
Slide 40: Focus on Power Brands with Brand Promotion and Marketing
Focus on Power Brands with Brand Promotion and Marketing Investments in Brand Promotion and Marketing Overview (In ₹ Crore) % of PCH 15% 15% 13% 11% sales CDMO 131 131 125 115 FY22 FY23 FY24 FY25 CHG Strong Growth in our Power Brands (In ₹ Crore) 26% CAGR PCH 538 448 Joint Venture 370 268 FY22 FY23
Slide 41: New Product Launches – An Important Driver of Growth
New Product Launches – An Important Driver of Growth Regular new product launches contributing to growth Overview New product and SKUs launches 63 CDMO 51 52 40 35 CHG FY21 FY22 FY23 FY24 FY25 200+ new products and SKUs launched in the last four years PCH NPDs launched in last 24 months contributed
Slide 42: Multi-channel Distribution Network and Tech-enabled Sales Coverage
Multi-channel Distribution Network and Tech-enabled Sales Coverage Overview Presence Across Traditional and Alternate Trade Channels Wide coverage across Strengthening presence Expanding presence on Direct-to-Customer (D2C) general trade and chemist in modern trade E-Commerce CDMO CHG Presence in ~1
Slide 43: Aspirations for FY2030
Aspirations for FY2030 Overview Become a US$ 200 Million1 Consumer Healthcare Company with Double-digits EBITDA Margins by FY2030 Driven By CDMO CHG PCH Scaling-up Power Omni-Channel Profitable Tech Enablement & Brands Expansion E-commerce Analytics Joint Venture 42 42 Notes: (1) Sales from own brand
Slide 44: JV with Abbvie
JV with Abbvie 6 Piramal Pharma Limited
Slide 45: Abbvie Therapeutics India Private Limited
Abbvie Therapeutics India Private Limited1 Joint Venture Arrangement Overview CDMO Ownership Ownership 49% 51% CHG In FY2025, the JV reported2 revenue of ₹ 493Cr with PAT margin of 28% PCH Continue to be one of 400+ Strong presence in Key Brands the market leaders in employees including glaucoma, dr
Slide 46: Shareholding Pattern and Listing Information
Shareholding Pattern and Listing Information Piramal Pharma Listing Information Public NSE Ticker PPLPHARMA 18% Promoter 35% BSE Ticker 543635 DII 15% Market Cap (Rs. Cr) 29,796 Share Outstanding (Lakhs) 13,257 FII 32% Promoter FII DII Public 45 45 The data is as on March 31,2025.
Slide 47: For Investor Queries
For Investor Queries: Gagan Borana Investor Relations and Enterprise Risk Management Email: gagan.borana@piramal.com Our Websites:- Piramal Pharma Limited www.piramalpharma.com Madhusudan Dalmia Investor Relations CDMO Email: madhusudan.dalmia@piramal.com www.piramalpharmasolutions.com Complex Hospi